Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Centessa Pharmaceuticals plc - American Depositary Shares (NQ:CNTA)

24.51 -0.97 (-3.81%)
Streaming Delayed Price Updated: 1:37 PM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Centessa Pharmaceuticals plc - American Depositary Shares

< Previous 1 2 3 4 Next >
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting
Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder 
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, appointed Chief Executive Officer and member of the Board of Directors 
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Wake Up to This Biotech Stock That Still Has Big Potential Upside
Centessa Pharmaceuticals released strong results in Phase 1 trials and now Wall Street analysts are buzzing over the stock. 
Via MarketBeat
News headline image
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
ORX142 is currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS) 
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
From Centessa Pharmaceuticals plc
Via GlobeNewswire
News headline image
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.